Penumbra Q4 revenue rises 22.1% to USD 385.4 million

Reuters

Feb 26

Penumbra Q4 revenue rises 22.1% to USD 385.4 million

Penumbra reported Q4 2025 revenue of USD 385.4 million, up 22.1%, and FY 2025 revenue of USD 1.4 billion, up 17.5%. Q4 operating income was USD 59.2 million (15.4% operating margin) and net income was USD 47.3 million (12.3% net income margin), while FY operating income was USD 189.2 million (13.5% operating margin) and net income was USD 177.7 million (12.7% net income margin). Adjusted EBITDA was USD 79.1 million in Q4 (20.5% margin) and USD 266.8 million for FY (19.0% margin). In Q4, U.S. thrombectomy revenue was USD 203.1 million, up 12.4%, and FY U.S. thrombectomy revenue was USD 771.5 million, up 19.3%. Q4 thrombectomy revenue totaled USD 254.7 million, up 15.7%, and embolization and access revenue was USD 130.7 million, up 37.0%; for FY, thrombectomy revenue was USD 947.9 million, up 16.2%, and embolization and access revenue was USD 455.7 million, up 20.2%. Penumbra said it will not provide FY 2026 guidance or host an earnings conference call due to the proposed acquisition by Boston Scientific.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Penumbra Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: SF90192) on February 25, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2614037455"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2614037455\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2614037455?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-26 02:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2614037455","market":"us","top_or_hot":-1,"title":"Penumbra Q4 revenue rises 22.1% to USD 385.4 million","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Penumbra Q4 revenue rises 22.1% to USD 385.4 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Penumbra reported Q4 2025 revenue of USD 385.4 million, up 22.1%, and FY 2025 revenue of USD 1.4 billion, up 17.5%. Q4 operating income was USD 59.2 million (15.4% operating margin) and net income was USD 47.3 million (12.3% net income margin), while FY operating income was USD 189.2 million (13.5% operating margin) and net income was USD 177.7 million (12.7% net income margin). Adjusted EBITDA was USD 79.1 million in Q4 (20.5% margin) and USD 266.8 million for FY (19.0% margin). In Q4, U.S. thrombectomy revenue was USD 203.1 million, up 12.4%, and FY U.S. thrombectomy revenue was USD 771.5 million, up 19.3%. Q4 thrombectomy revenue totaled USD 254.7 million, up 15.7%, and embolization and access revenue was USD 130.7 million, up 37.0%; for FY, thrombectomy revenue was USD 947.9 million, up 16.2%, and embolization and access revenue was USD 455.7 million, up 20.2%. Penumbra said it will not provide FY 2026 guidance or host an earnings conference call due to the proposed acquisition by Boston Scientific.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/PEN\">Penumbra Inc</a>. published the original content used to generate this news brief via PR Newswire (Ref. ID: SF90192) on February 25, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Penumbra Q4 revenue rises 22.1% to USD 385.4 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPenumbra Q4 revenue rises 22.1% to USD 385.4 million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-26 02:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Penumbra Q4 revenue rises 22.1% to USD 385.4 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Penumbra reported Q4 2025 revenue of USD 385.4 million, up 22.1%, and FY 2025 revenue of USD 1.4 billion, up 17.5%. Q4 operating income was USD 59.2 million (15.4% operating margin) and net income was USD 47.3 million (12.3% net income margin), while FY operating income was USD 189.2 million (13.5% operating margin) and net income was USD 177.7 million (12.7% net income margin). Adjusted EBITDA was USD 79.1 million in Q4 (20.5% margin) and USD 266.8 million for FY (19.0% margin). In Q4, U.S. thrombectomy revenue was USD 203.1 million, up 12.4%, and FY U.S. thrombectomy revenue was USD 771.5 million, up 19.3%. Q4 thrombectomy revenue totaled USD 254.7 million, up 15.7%, and embolization and access revenue was USD 130.7 million, up 37.0%; for FY, thrombectomy revenue was USD 947.9 million, up 16.2%, and embolization and access revenue was USD 455.7 million, up 20.2%. Penumbra said it will not provide FY 2026 guidance or host an earnings conference call due to the proposed acquisition by Boston Scientific.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/PEN\">Penumbra Inc</a>. published the original content used to generate this news brief via PR Newswire (Ref. ID: SF90192) on February 25, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2265009873.SGD","symbol_name":"Eastspring Investments - Global Growth Equity AS SGD-H","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260225:nNDLbHQxnP:1","article_id":"2614037455","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2614037455","pubTimestamp":1772042493,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Penumbra reported Q4 2025 revenue of USD 385.4 million, up 22.1%, and FY 2025 revenue of USD 1.4 billion, up 17.5%. Q4 operating income was USD 59.2 million  and net income was USD 47.3 million , while FY operating income was USD 189.2 million  and net income was USD 177.7 million . Adjusted EBITDA was USD 79.1 million in Q4  and USD 266.8 million for FY . In Q4, U.S. thrombectomy revenue was USD 203.1 million, up 12.4%, and FY U.S. thrombectomy revenue was USD 771.5 million, up 19.3%. Q4 thrombectomy revenue totaled USD 254.7 million, up 15.7%, and embolization and access revenue was USD 130.7 million, up 37.0%; for FY, thrombectomy revenue was USD 947.9 million, up 16.2%, and embolization and access revenue was USD 455.7 million, up 20.2%. Penumbra said it will not provide FY 2026 guidance or host an earnings conference call due to the proposed acquisition by Boston Scientific.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2265009873.SGD":"Eastspring Investments - Global Growth Equity AS SGD-H","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","BSX":"波士顿科学","LU0345769128.USD":"NINETY ONE GSF GLOBAL EQUITY \"A\" (USD) ACC","LU0267386448.USD":"FIDELITY FIRST ALL COUNTRY WORLD \"A\" (USD) INC","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","LU1548497426.USD":"安联环球人工智能AT Acc","LU0187121727.USD":"FIDELITY SUSTAINABLE US EQUITY \"A\" (USD) INC","LU1989771016.USD":"东方汇理环球老龄化投资基金 A2 Acc","LU0345769631.USD":"NINETY ONE GSF GLOBAL EQUITY \"A\" (USD) INC","LU0251132253.USD":"FIDELITY FUNDS  GLOBAL THEMATIC OPPORTUNITIES \"A\" (USD) ACC","LU1989772840.SGD":"CPR Invest - Climate Action A2 Acc SGD-H","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU2362541273.HKD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (HKD) ACC","LU0077335932.USD":"FIDELITY AMERICAN GROWTH \"A\" INC","SG9999001176.USD":"United Global Healthcare Acc USD","LU0823417737.USD":"BNP PARIBAS SUSTAINABLE GLOBAL LOW VOL EQUITY \"C\" (USD) INC","LU2506951958.HKD":"BNP PARIBAS SUSTAINABLE GLOBAL LOW VOL EQUITY \"CRH\" (HKDHDG) INC","LU1989772923.USD":"CPR Invest - Climate Action A2 Acc USD-H","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","BK4585":"ETF&股票定投概念","LU0353189680.USD":"富国美国全盘成长基金Cl A Acc","LU2491049909.HKD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (HKD) ACC","LU0528227936.USD":"富达环球人口趋势基金A-ACC","PEN":"Penumbra Inc","LU1720051017.SGD":"Allianz Global Artificial Intelligence AT Acc H2-SGD","LU2506952170.USD":"BNP PARIBAS SUSTAINABLE GLOBAL LOW VOL EQUITY \"CRH\" (USDHDG) INC","LU1989764748.USD":"东方汇理环球颠覆性机遇A2 Acc","LU2362540622.SGD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (SGDHDG) ACC","LU0432979614.USD":"JPM GLOBAL HEALTHCARE \"A\" ACC","LU2357305700.SGD":"Allianz Global Artificial Intelligence ET H2-SGD","LU0238689110.USD":"贝莱德环球动力股票基金","LU2112291526.USD":"BGF WORLD HEALTHSCIENCE \"A4\" (USD) INC","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU1804176565.USD":"EASTSPRING INV GLOBAL GROWTH EQUITY \"A\" (USD) ACC","LU0353189763.USD":"ALLSPRING  US ALL CAP GROWTH FUND \"I\" (USD) ACC","LU1791710582.SGD":"Fidelity Global Demographics A-ACC-SGD (SGD/USD hedged)","BK4082":"医疗保健设备","LU1366192091.USD":"ALLIANZ US EQUITY PLUS \"AM\" (USD) INC","LU1718418525.SGD":"JPMorgan Investment Funds - Global Select Equity A (acc) SGD","LU2491050154.USD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (USD) ACC","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU1791710400.SGD":"Fidelity Global Demographics A-ACC-SGD","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","BK4588":"碎股","LU0882574055.USD":"富达全球健康医疗A ACC"},"translate_title":"Penumbra第四季度收入增长22.1%至3.854亿美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BSX":0.9,"PEN":0.9},"content_text":"Penumbra Q4 revenue rises 22.1% to USD 385.4 million\n    \n\n        Penumbra reported Q4 2025 revenue of USD 385.4 million, up 22.1%, and FY 2025 revenue of USD 1.4 billion, up 17.5%. Q4 operating income was USD 59.2 million (15.4% operating margin) and net income was USD 47.3 million (12.3% net income margin), while FY operating income was USD 189.2 million (13.5% operating margin) and net income was USD 177.7 million (12.7% net income margin). Adjusted EBITDA was USD 79.1 million in Q4 (20.5% margin) and USD 266.8 million for FY (19.0% margin). In Q4, U.S. thrombectomy revenue was USD 203.1 million, up 12.4%, and FY U.S. thrombectomy revenue was USD 771.5 million, up 19.3%. Q4 thrombectomy revenue totaled USD 254.7 million, up 15.7%, and embolization and access revenue was USD 130.7 million, up 37.0%; for FY, thrombectomy revenue was USD 947.9 million, up 16.2%, and embolization and access revenue was USD 455.7 million, up 20.2%. Penumbra said it will not provide FY 2026 guidance or host an earnings conference call due to the proposed acquisition by Boston Scientific.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Penumbra Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: SF90192) on February 25, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}